Search
Interviews with the world’s key opinion leaders in cancer
Gilles Salles

Rituximab Maintenance Cuts Follicular Lymphoma Recurrence Risk In Half — Phase III PRIMA Study Results

June 28, 2010
AudioMedica News
AudioMedica News
Rituximab Maintenance Cuts Follicular Lymphoma Recurrence Risk In Half — Phase III PRIMA Study Results
Loading
/
Gilles Salles
Gilles Salles, University of Lyon

Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with rituximab for two years compared with those who did not. Gilles Salles from the University of Lyon discussed his findings with Peter Goodwin during the 2010 European Hematology Association annual congress in Barcelona.



LISTEN

[audio:https://www.audiomedica.com/podcasting/otbn/100611GillesSallesPodcastOTBN.mp3]

2 comments

  • Had F. L. since 9-1-2000 . 2 chemo, 1 with rituxin. 2 relapses. just treated with rituxin. No relapse in 4 years. cancer free as of 8-1-2010.
    being treated by Dr. Stewart at MUSC
    Charleston SC. Really been lucky.
    John Peters

  • John Peters, i’m go happy for you! i have been diagnosed with FL and currently undergoing chemo (4th). I’ve been told i need to choose a follow up therapy. Either Rituxin every 3 months, or Zevalin.

Further reading

Menu